Tarsus Pharmaceuticals, Inc.
TARS
$46.47
$2.906.66%
| 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | 12/31/2023 | |
|---|---|---|---|---|---|
| Revenue | 407.86% | 2,471.78% | -- | 1,004.56% | 30.76% |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 407.86% | 2,471.78% | -- | 1,004.56% | 30.76% |
| Cost of Revenue | 50.12% | 23.14% | 22.13% | -- | 39.25% |
| Gross Profit | 3,187.13% | 408.62% | 303.17% | 938.40% | -237.62% |
| SG&A Expenses | 60.52% | 90.97% | 189.97% | 241.67% | 193.89% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 57.89% | 71.19% | 125.82% | 137.86% | 129.54% |
| Operating Income | 45.06% | 38.53% | -1.47% | -51.03% | -195.13% |
| Income Before Tax | 44.84% | 40.18% | -5.94% | -52.57% | -208.13% |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | 44.84% | 40.18% | -5.94% | -52.57% | -208.13% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 44.84% | 40.18% | -5.94% | -52.57% | -208.13% |
| EBIT | 45.06% | 38.53% | -1.47% | -51.03% | -195.13% |
| EBITDA | 45.61% | 38.86% | -1.30% | -50.57% | -194.75% |
| EPS Basic | 54.30% | 52.27% | 24.89% | -15.59% | -157.60% |
| Normalized Basic EPS | 57.19% | 52.09% | 29.36% | -13.44% | -142.18% |
| EPS Diluted | 54.30% | 52.27% | 24.89% | -15.02% | -157.60% |
| Normalized Diluted EPS | 57.19% | 52.09% | 29.36% | -13.44% | -142.18% |
| Average Basic Shares Outstanding | 20.71% | 25.34% | 41.05% | 32.00% | 19.60% |
| Average Diluted Shares Outstanding | 20.71% | 25.34% | 41.05% | 32.00% | 19.60% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |
